Our previous study reported elevated PUFA levels in isolated HDLs from patients with GCK-MODY mediated with enhanced adipose triglyceride lipase (ATGL) and choline/ethanolamine phosphotransferase 1 (CEPT1), which may further promote the atheroprotective effect.4 This result raises concern about the side effects on cardiovascular events with long-term GCK agonist use in T2DM treatment. The gene discussed is CEPT1; the disease is type 2 diabetes mellitus.